---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-26-000023"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2026-09-21T20:34:25+00:00"
generated_at: "2026-09-21T20:37:35.328949+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PTC completes acquisition of ST-920 Fabry gene therapy from Sangamo; BLA submission expected Q4 2026

## Summary
- Completed acquisition of ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics.
- Rolling BLA submission to FDA for accelerated approval expected to be completed in Q4 2026.
- BLA based on 52-week Phase 1/2 STAAR study showing favorable renal function effect and safety/tolerability.
- Company also plans to pursue regulatory approval of ST-920 outside the United States.
- CEO Matthew Klein cites potential to address limitations of chronic enzyme replacement therapy for Fabry community.

## SEC filing metadata
- accession: 0001070081-26-000023
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2026-09-21T20:34:25+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008126000023/0001070081-26-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008126000023/tmb-20260921x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-26-000023
- JSON: https://secwatch.observer/filing/0001070081-26-000023.json
- Plain text: https://secwatch.observer/filing/0001070081-26-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.